Home/ Stocks/ ALLR

Allarity Therapeutics, Inc. Common Stock

ALLR XNAS

$1.36 -0.03 (-2.14%) ▼ 15-min delayed

Open

$1.42

High

$1.43

Low

$1.25

Volume

152.2K

Market Cap

$22.28M

About Allarity Therapeutics, Inc. Common Stock

Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States. It is focused on the clinical development of its lead program: Stenoparib, which is being co-developed with a drug specific DRP companion diagnostic.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 8 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	$25.0K	$-2,750,000	$-0.17
FY 2025	$320.0K	$-11,231,000	$-0.78
Q3 2025	$0	$-2,806,000	$-0.19
Q2 2025	$0	$-2,320,000	$-0.15

Related Market News

No specific coverage for ALLR yet. Check out our latest market news or earnings calendar.

Get ALLR Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Allarity Therapeutics, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.